[go: up one dir, main page]

ES2150233T3 - Pirrolo(2,3-c)carbazol-6-onas condensadas que potencian la actividad de interferon gamma. - Google Patents

Pirrolo(2,3-c)carbazol-6-onas condensadas que potencian la actividad de interferon gamma.

Info

Publication number
ES2150233T3
ES2150233T3 ES97914792T ES97914792T ES2150233T3 ES 2150233 T3 ES2150233 T3 ES 2150233T3 ES 97914792 T ES97914792 T ES 97914792T ES 97914792 T ES97914792 T ES 97914792T ES 2150233 T3 ES2150233 T3 ES 2150233T3
Authority
ES
Spain
Prior art keywords
pyrrollo
onas
carbazol
condensed
promote
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97914792T
Other languages
English (en)
Inventor
Robert L Hudkins
James L Diebold
Ernest Knight Jr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cephalon LLC
Original Assignee
Cephalon LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon LLC filed Critical Cephalon LLC
Application granted granted Critical
Publication of ES2150233T3 publication Critical patent/ES2150233T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

EN ESTA PATENTE SE DESCRIBEN LAS MOLECULAS SINTETICAS Y BIOLOGICAMENTE ACTIVAS DENOMINADAS PIRROLO(2,3-C)CARBAZOL - 6ONAS. ESTAS MOLECULAS SE REPRESENTAN MEDIANTE LAS FORMULAS GENERALES (I) Y (II). TAMBIEN SE DESCRIBEN LOS METODOS PARA LA PREPARACION Y USO DE LAS PIRROLO(2,3 - C)CARBAZOL - 6 - ONAS CONDENSADAS.
ES97914792T 1996-02-21 1997-02-20 Pirrolo(2,3-c)carbazol-6-onas condensadas que potencian la actividad de interferon gamma. Expired - Lifetime ES2150233T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/604,474 US5616724A (en) 1996-02-21 1996-02-21 Fused pyrrolo[2,3-c]carbazole-6-ones

Publications (1)

Publication Number Publication Date
ES2150233T3 true ES2150233T3 (es) 2000-11-16

Family

ID=24419747

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97914792T Expired - Lifetime ES2150233T3 (es) 1996-02-21 1997-02-20 Pirrolo(2,3-c)carbazol-6-onas condensadas que potencian la actividad de interferon gamma.

Country Status (17)

Country Link
US (2) US5616724A (es)
EP (1) EP0885229B1 (es)
JP (1) JP2000505458A (es)
KR (1) KR19990087074A (es)
CN (1) CN1098266C (es)
AT (1) ATE195124T1 (es)
AU (1) AU716265B2 (es)
BR (1) BR9707659A (es)
DE (1) DE69702705T2 (es)
DK (1) DK0885229T3 (es)
ES (1) ES2150233T3 (es)
GR (1) GR3034533T3 (es)
HK (1) HK1017673A1 (es)
NZ (1) NZ330837A (es)
PT (1) PT885229E (es)
RU (1) RU2193037C2 (es)
WO (1) WO1997031002A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6127401A (en) * 1998-06-05 2000-10-03 Cephalon, Inc. Bridged indenopyrrolocarbazoles
US7795246B2 (en) * 1998-08-06 2010-09-14 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
US6200968B1 (en) 1998-08-06 2001-03-13 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
CA2345295C (en) * 1998-09-25 2009-12-15 Cephalon, Inc. Use of fused pyrrolocarbazoles in preventing/treating damage to sensory hair cells and cochlear neurons
US6656474B1 (en) * 1999-01-15 2003-12-02 Regeneron Pharmaceuticals, Inc. Methods of using a neurotrophin and its analogues for the treatment of gastrointestinal hypomotility disorders
US6841567B1 (en) * 1999-02-12 2005-01-11 Cephalon, Inc. Cyclic substituted fused pyrrolocarbazoles and isoindolones
US6399780B1 (en) * 1999-08-20 2002-06-04 Cephalon, Inc. Isomeric fused pyrrolocarbazoles and isoindolones
FR2798931B1 (fr) * 1999-09-22 2001-11-16 Oreal Nouveaux composes indoliques, leur utilisation pour la teinture et le maquillage des matieres keratiniques, compositions les contenant et procedes de teinture
US20030199043A1 (en) 2000-04-12 2003-10-23 Ballance David J. Albumin fusion proteins
US6630500B2 (en) * 2000-08-25 2003-10-07 Cephalon, Inc. Selected fused pyrrolocarbazoles
AR035971A1 (es) * 2001-05-16 2004-07-28 Cephalon Inc Metodos para el tratamiento y la prevencion del dolor
JP5424521B2 (ja) 2001-12-21 2014-02-26 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド アルブミン融合タンパク質
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
US7169802B2 (en) * 2003-12-23 2007-01-30 Cephalon, Inc. Fused pyrrolocarbazoles
US7241779B2 (en) * 2003-12-23 2007-07-10 Cephalon, Inc. Fused pyrrolocarbazoles
US20060134175A1 (en) * 2004-12-22 2006-06-22 Stephen Bartels Drug eluting pharmaceutical delivery system for treatment of ocular disease and method of use
US20060134174A1 (en) * 2004-12-22 2006-06-22 Bausch & Lomb Incorporated Pharmaceutical delivery system and method of use
US20060134176A1 (en) * 2004-12-22 2006-06-22 Bausch & Lomb Incorporated Pharmaceutical delivery system and method of use
WO2007002670A2 (en) * 2005-06-28 2007-01-04 Bausch & Lomb Incorporated Method of lowering intraocular pressure
WO2009067221A2 (en) * 2007-11-20 2009-05-28 Cephalon, Inc. Microemulsion containing indolocarbazole compound and dosage forms containing the same
NZ592868A (en) * 2008-11-19 2012-08-31 Cephalon Inc Novel forms of an indazolo [5,4-a] pyrrolo [3,4-c] carbazole compound
EP2192121A1 (en) 2008-11-27 2010-06-02 Cephalon France Regioselective reduction of fused pyrrolocarbazoles-5,7-diones

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4552842A (en) * 1983-01-28 1985-11-12 Bristol-Myers Company Process for producing rebeccamycin
EP0303697B1 (en) * 1987-03-09 1997-10-01 Kyowa Hakko Kogyo Co., Ltd. Derivatives of physiologically active substance k-252
DE3835842A1 (de) * 1988-10-21 1990-04-26 Goedecke Ag Indolocarbazol-derivate, verfahren zu deren herstellung und deren verwendung als arzneimittel
CZ280738B6 (cs) * 1988-02-10 1996-04-17 F. Hoffmann - La Roche And Co., Aktiengesellschaft Substituované pyrroly, jejich použití pro výrobu léčiv a léčiva na jejich bázi
DE3833008A1 (de) * 1988-09-29 1990-04-05 Goedecke Ag Pyrrolocarbozol-derivate, verfahren zu deren herstellung und deren verwendung als arzneimittel
MC2096A1 (fr) * 1989-02-23 1991-02-15 Hoffmann La Roche Pyrroles substitues
DK0506836T3 (da) * 1989-12-20 1994-11-28 Schering Corp BCRF1 proteiner som inhibitorer for interferon-gamma
DE3942296A1 (de) * 1989-12-21 1991-06-27 Goedecke Ag Indolocarbazol-derivate, verfahren zu deren herstellung und deren verwendung
US5185260A (en) * 1991-08-29 1993-02-09 The United States Of America As Represented By The United States Department Of Energy Method for distinguishing normal and transformed cells using G1 kinase inhibitors
NZ245203A (en) * 1991-11-29 1997-07-27 Banyu Pharma Co Ltd 5h-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6h)-dione derivatives substituted in position-13 by a pentose or hexose group; corresponding indolo-furano(anhydride)intermediates
US6271242B1 (en) * 1992-02-10 2001-08-07 Bristol-Myers Squibb Co. Method for treating cancer using a tyrosine protein kinase inhibitor
US5405864A (en) * 1993-10-15 1995-04-11 Syntex (U.S.A.) Inc. Chemotherapeutic maleimides

Also Published As

Publication number Publication date
DE69702705T2 (de) 2001-04-05
NZ330837A (en) 1999-03-29
GR3034533T3 (en) 2001-01-31
DE69702705D1 (de) 2000-09-07
CN1098266C (zh) 2003-01-08
US5616724A (en) 1997-04-01
PT885229E (pt) 2000-12-29
KR19990087074A (ko) 1999-12-15
AU2191497A (en) 1997-09-10
HK1017673A1 (en) 1999-11-26
US5801190A (en) 1998-09-01
EP0885229A1 (en) 1998-12-23
BR9707659A (pt) 1999-04-13
JP2000505458A (ja) 2000-05-09
ATE195124T1 (de) 2000-08-15
AU716265B2 (en) 2000-02-24
WO1997031002A1 (en) 1997-08-28
RU2193037C2 (ru) 2002-11-20
EP0885229B1 (en) 2000-08-02
CN1211254A (zh) 1999-03-17
DK0885229T3 (da) 2000-10-16

Similar Documents

Publication Publication Date Title
ES2150233T3 (es) Pirrolo(2,3-c)carbazol-6-onas condensadas que potencian la actividad de interferon gamma.
DK0751959T3 (da) Modificerede polypeptider med forøget biologisk aktivitet
EA199800946A1 (ru) Концентрированный препарат антител
ATE182892T1 (de) Mercaptoacetylamide von pyridazo(1,2-a>(1,2>- diazepin -derivaten als eukephalinase und ace- inhibitoren
ID23374A (id) Halogenopirimidin
NO963239L (no) Klorpyrimid-mellomprodukter
TR200000197T2 (tr) Yeni bileşimler
TR200003513T2 (tr) Pirolo[2,3d]Pirimidin kompozisyonları ve kullanımları
DE69710490D1 (de) Triazolo(4,5-d)pyrimidinyl-derivate und ihre verwendung als medikamente
BG101748A (en) Heterocyclic condensated pyridines
ES8801930A1 (es) Procedimiento para la preparacion de dipeptidos de n,n'-dialquilguanidino
PT1017659E (pt) Tetra-hidronaftalenos substituidos e compostos analogos
BG101892A (en) Sugar-modified cytostatics
UA29466C2 (uk) Фармацевтична композиція з антипухлинною активністю
BG103968A (en) Pharmaceutical antiviral composition containing glycirricinic acid and at least one protein with antiviral activity
GB9807114D0 (en) Novel process
FI945164A0 (fi) Biologisesti aktiivisesti ureidojohdannaiset, jotka ovat käyttökelpoisia antimetastaattisina aineina
EA199900260A1 (ru) Кристаллический фармацевтический продукт
CA2241852A1 (en) Fused pyrrolo(2,3-c)carbazole-6-ones which potentiate activity of gamma interferon
EA199900959A1 (ru) Способы снижения содержания фибриногена
BR9407232A (pt) Compostos de tiocarbamoíla
SE9604439D0 (sv) New receptor
MD369C2 (ro) Imunizator chimic al plantelor de tutun
DK0858465T3 (da) Protein med antitumorvirkning.
MX9603809A (es) Preparado combinado farmaceutico con ketoprofeno.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 885229

Country of ref document: ES